Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Triveni Bio

Explore full profile

Pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders

Waltham, United StatesBiotech & Life Sciences
Valuation $500M–1B Latest valuation · 2026
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Triveni Bio and the history behind them.

About Triveni Bio

Triveni Bio is at the forefront of genetics-informed precision medicine, focusing on the development of functional antibodies to treat immunological and inflammatory disorders. Utilizing a proprietary platform, the company identifies and mitigates risks associated with novel therapeutic targets that have strong genetic rationale. This platform also enables the prediction and stratification of patient subpopulations, providing valuable insights into disease mechanisms. Triveni Bio serves the biopharmaceutical market, targeting healthcare providers and researchers who require advanced therapeutic solutions. The company operates on a business-to-business (B2B) model, generating revenue through the development and licensing of its proprietary antibodies and related technologies.

Source: Dealroom company data

At a glance

Status
Operational
Headquarters
Waltham, United States
Employees
56
Open positions
2
Dealroom signal
0.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Client focus
b2b
Links
WebsiteLinkedIn

Latest news

Press, funding announcements and product moves mentioning Triveni Bio.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jun 2026 $65M $575M Deep Track Capital · Janus Henderson Investors · Ascenta Capital ↗
SERIES BOther financing Oct 2024 $115M $460M OrbiMed · Viking Global Investors · Cormorant Asset Management · Atlas Venture ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Triveni Bio website traffic

Latest recorded traffic for Triveni Bio is 4.3K monthly website visits, up 22.9% over the last three months. Triveni Bio's team grew 833.3% over the past year.

Latest monthly visits4.3K 3-month web change+22.9% 1-year team growth+833.3%
Monthly website visitsOct 2023–Jul 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
Senior Scientist, Translational ResearchWatertown, MA · Other · Jul 19, 2026 Senior Research Associate, BiologicsWatertown, MA · Other · Jul 11, 2026
2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
VodorasloYour solution to better air quality Sofia, Bulgaria Operational 1 $61K $132K
Normax BiomedNormax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness Cork, Ireland Operational
ENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets Medford, United States Operational
LTZ TherapeuticsDevelops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need Redwood City, United States Operational
AtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance L'Hospitalet de Llobregat, Spain Operational
Teitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases Aarhus, Denmark Operational
Rivus PharmaceuticalsOperates as a biopharmaceutical company dedicated to improving cardio-metabolic health Charlottesville, United States Operational
Kintsugi TherapeuticsDevelopment of ER stress inhibitors for the treatment of metabolic diseases Barcelona, Spain Operational
Showing 8 of the closest matchesCompare every metric →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A14 investors entered at this stage

Series B and later2 investors entered at this stage

Talent

Book a demo to see the people
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Triveni Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Triveni Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.